Celltrion, Nan Fung Group form JV to market Biosimilars in China

Korea headquartered Celltrion and Hong Kong, S.A.R., China based Nan Fung Group have announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties.

At the formation of the Joint Venture, Vcell Healthcare Limited has simultaneously signed a licensing agreement with Celltrion Group. Vcell Healthcare Limited will obtain the exclusive rights in mainland China to develop, manufacture and commercialize three US FDA and EMA approved biosimilar products from Celltrion: CT-P13 (Remsima), CT-P10 (Truxima) and CT-P6 (Herzuma). Remsima, referencing Remicade (Infliximab), was the first antibody biosimilar approved in the EU and US.

Remsima has been commercialized in more than 80 countries worldwide. Truxima, referencing Rituxan (Rituximab), has been approved in the US and EU; and Herzuma, referencing Herceptin (Trastuzumab), has been approved in the US, the EU and Japan.

Vcell Healthcare Limited aims to launch these products in China expeditiously following the regulatory approval process. In the meantime, Celltrion and Nan Fung Group will collectively explore the opportunity to develop a world-class biologics manufacturing facility in China.